The Lysol and Mucinex maker is investing in domestic R&D and expanding its largest plant by half.
Reckitt, the health and hygiene company known for Lysol and Mucinex, has allotted $600 million to upgrade its U.S. operations, according to Fierce Pharma. The investment will fund an R&D hub at its new headquarters and finalize an expansion of its largest manufacturing site.
The expansion will enlarge that site by 50%, the report says. Reckitt operates seven manufacturing sites in the U.S. Since this summary is based on a single source, there are no differing accounts to compare.
New research links detectable blood levels of tetrachloroethylene to a threefold higher likelihood of significant liver scarring.
New estimates put cancer's global toll at 21 million diagnoses in 2024 and warn the burden will grow sharply.
A detailed map of breast tumors reveals hibernating cancer cells that may survive treatment and drive later recurrence.
A large study of over 270,000 people suggests that higher blood levels of tyrosine, a common supplement ingredient, may shorten male lifespan.